Jefferies reiterates PPDI at buy

Jefferies & Co., Inc. analyst David Windley reiterated Pharmaceutical Product Development, Inc. (PPDI) at buy and maintained his $44.50 price target on the belief that the company's growth opportunities are turning more positive. PPDI reported third-quarter earnings per share of $0.31, in line with consensus though a penny light of Jefferies' estimate. Shares of the Wilmington, N.C.-based pharmaceutical company were up 88 cents, or 2.47%, at $36.56. (Nasdaq: PPDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.